These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 22034894)

  • 1. Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production.
    Kats-Ugurlu G; Maass C; van Herpen C; de Waal R; Oosterwijk E; Mulders P; Hulsbergen-van de Kaa C; Leenders W
    Histopathology; 2011 Sep; 59(3):562-4. PubMed ID: 22034894
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical results of Nexavar for the treatment of kidney cancer].
    Escudier B
    Prog Urol; 2007 Feb; 17(1 Suppl 1):150-3. PubMed ID: 17571640
    [No Abstract]   [Full Text] [Related]  

  • 3. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
    Albiges L; Salem M; Rini B; Escudier B
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib in renal cell carcinoma.
    Flaherty KT
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):747s-752s. PubMed ID: 17255304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
    Raspollini MR
    Curr Oncol Rep; 2007 Sep; 9(5):331. PubMed ID: 17706159
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecule of the month. Sorafenib.
    Drug News Perspect; 2006 Mar; 19(2):119. PubMed ID: 16628266
    [No Abstract]   [Full Text] [Related]  

  • 7. [Third-line therapy for metastasized renal cell carcinoma: a randomized, multicenter non-blinded phase III study to compare safety and effectiveness of TF1258 versus sorafenib in patients with metastasized renal cell carcinoma following failure of antiangiogenic (VEGF targeted and mTOR inhibition) therapy (GOLD-AN 31/11 of the Working Group Urological Oncology)].
    Rexer H
    Urologe A; 2011 Oct; 50(10):1319-21. PubMed ID: 21976121
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib for the management of advanced renal cell carcinoma.
    Escudier B
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):825-36. PubMed ID: 21707277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib: delivering a targeted drug to the right targets.
    Flaherty KT
    Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure.
    Ruppin S; Protzel C; Klebingat KJ; Hakenberg OW
    Eur Urol; 2009 Apr; 55(4):986-8; quiz 988. PubMed ID: 19004541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
    Xie XD; Piao Y; Liu ZZ
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):714-5. PubMed ID: 20021872
    [No Abstract]   [Full Text] [Related]  

  • 12. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
    J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.
    Bellmunt J; Fishman M; Eisen T; Quinn D
    Expert Rev Anticancer Ther; 2010 Jun; 10(6):825-35. PubMed ID: 20553208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib [corrected] in kidney cancer.
    Escudier B
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix90-3. PubMed ID: 17631603
    [No Abstract]   [Full Text] [Related]  

  • 15. [Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
    Schrader AJ; Hegele A; Olbert P; Buer J; Jeron A; Hofmann R
    Urologe A; 2007 Sep; 46(9):1291. PubMed ID: 17668165
    [No Abstract]   [Full Text] [Related]  

  • 16. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
    Eng FC; Easson AM; Szentgyorgyi E; Knox JJ
    Eur J Surg Oncol; 2009 Feb; 35(2):219-21. PubMed ID: 17976949
    [No Abstract]   [Full Text] [Related]  

  • 17. [Molecular targeted therapy for advanced renal cell carcinoma].
    Kanayama H
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1208-13. PubMed ID: 20647700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of synergistic antitumor effect of sorafenib and interferon-α on treatment of renal cell carcinoma.
    Takeuchi A; Eto M; Tatsugami K; Yamada H; Oki T; Kiyoshima K; Yoshikai Y; Naito S
    J Urol; 2010 Dec; 184(6):2549-56. PubMed ID: 21030044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation.
    Miyake H; Kurahashi T; Yamanaka K; Kondo Y; Takenaka A; Inoue TA; Fujisawa M
    BJU Int; 2010 Dec; 106(11):1643-7. PubMed ID: 20553261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
    Bukowski RM; Stadler WM; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Figlin RA
    Oncology; 2010; 78(5-6):340-7. PubMed ID: 20733337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.